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Post-Effectiveness of Distal Embolic Protection
or Patients Undergoing Percutaneous
ntervention of Saphenous Vein Bypass Grafts
esults From the SAFER Trial
avid J. Cohen, MD, MSC,*† Sabina A. Murphy, MSC,* Donald S. Baim, MD,‡ Tara A. Lavelle, BS,*
onna H. Berezin, MPH,* Donald E. Cutlip, MD,*† Kalon K. L. Ho, MD, MSC,*†
ichard E. Kuntz, MD, MSC,*‡ on behalf of the SAFER Trial Investigators
oston, Massachusetts
OBJECTIVES The goal of this research was to determine the incremental cost and cost-effectiveness of
embolic protection in patients undergoing percutaneous revascularization (PCI) of diseased
saphenous vein bypass grafts (SVGs).
BACKGROUND Distal protection using the GuardWire balloon occlusion device has been shown to reduce
major ischemic complications in patients undergoing SVG PCI, but the cost-effectiveness of
this approach is unknown.
METHODS We prospectively measured medical resource utilization and cost for 801 patients undergoing
SVG intervention who were randomized to distal protection using the GuardWire (n  406)
or conventional treatment (n  395) in the Saphenous Vein Graft Angioplasty Free of
Emboli Randomized (SAFER) trial. Long-term survival and cost-effectiveness were pro-
jected based on observed 30-day outcomes and a validated survival model for postcoronary
artery bypass graft patients.
RESULTS Compared with conventional treatment, distal protection increased initial procedural costs by
$1,600 ($6,326 vs. $4,779, p 0.001). However, by reducing ischemic complications, distal
protection reduced mean length of stay by 0.4 days and other hospital costs by nearly $1,000
($6,846 vs. $7,811, p  0.018). As a result, overall initial hospital costs were only $582 per
patient higher with distal protection. Based on the observed 30-day cost and outcome
differences in the trial, the incremental cost-effectiveness ratio for distal protection was $3,718
per year of life saved and remained $40,000 per year of life saved in 97.3% of bootstrap
simulations (95% confidence interval, $0 to $43,079).
CONCLUSIONS For patients undergoing PCI of diseased SVGs, distal protection using the GuardWire
system is an attractive use of limited health care resources. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.0861801–8) © 2004 by the American College of Cardiology Foundation
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wespite major advances in catheter-based therapy and
djunctive pharmacology, percutaneous revascularization of
iseased saphenous vein bypass grafts (SVGs) remains a
ritical challenge for the interventional cardiologist. Vein
raft lesions are frequently associated with considerable
See page 1809
laque burden and intracoronary thrombus, which may
redispose to complications including distal embolization,
he no-reflow phenomenon, and periprocedural myocardial
nfarction (MI) (1). Moreover, patients with diseased SVGs
requently have additional characteristics including ad-
anced age, more extensive atherosclerosis, and reduced left
entricular function such that they tolerate embolic compli-
ations less well than a “typical” patient (2,3). Thus,
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nc.t
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ccepted May 4, 2004.pproaches to minimize these complications in patients
ndergoing vein graft PCI are of paramount importance.
Over the past two decades, a wide range of mechanical
nd pharmacologic strategies including atherectomy (4),
hrombectomy (5,6), intracoronary stenting (7), prolonged
nfusions of thrombolytic therapy (6), and glycoprotein
Ib/IIIa antagonists (8) have been attempted for patients
ndergoing SVG intervention, with limited success. Re-
ently, however, distal embolic protection using a novel
alloon-occlusion device (PercuSurge GuardWire, Medtronic
nc., Minneapolis, Minnesota) has been shown to substan-
ially reduce major complications in this patient population
9).
Although the GuardWire is relatively expensive ($1,500
er device), embolic complications are frequent and costly in
atients undergoing SVG percutaneous coronary interven-
ion (PCI) (10). Thus, it is possible that avoidance of such
vents could offset much of the cost of the device. Moreover,
ven if the full cost of the device were not recouped, embolic
rotection could be cost-effective if the benefits of such
herapy (e.g., reduced mortality and procedure-related MI)
ere commensurate with the additional cost (11). We,herefore, conducted a prospective economic study in con-
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Cost-Effectiveness of Distal Embolic Protection November 2, 2004:1801–8unction with the Saphenous Vein Graft Angioplasty Free
f Emboli Randomized (SAFER) trial—a randomized
linical trial to evaluate the safety and effectiveness of distal
mbolic protection in patients undergoing SVG intervention.
ETHODS
atient population and treatment protocol. Between Jan-
ary 1999 and August 2000, 801 patients undergoing PCI
or a stenotic saphenous vein graft were enrolled in the
AFER trial. Details of the study design have been de-
cribed previously (9). Patients were eligible if they were
ndergoing planned PCI to an SVG with a reference
iameter between 3 and 6 mm. Patients with ongoing MI,
jection fraction 25%, serum creatinine 2.5 mg/dl, or
equiring multivessel PCI were excluded. For the first 142
atients enrolled, lesion length was required to be
one-third of total graft length, but no upper limit on
esion length was imposed for the subsequent 659 patients.
he study protocol was approved by the institutional review
oard at each site, and each patient provided informed
onsent before enrollment.
Patients were randomized to either conventional PCI
control group, n  395) or PCI using the PercuSurge
uardWire balloon occlusion device (GuardWire group, n
406), stratified by clinical site and by whether the
perator planned to use a glycoprotein IIb/IIIa receptor
ntagonist. Conventional PCI was performed over a stan-
ard angioplasty guidewire using balloon expandable or
elf-expanding coronary stents. Patients assigned to the
uardWire group underwent PCI using the GuardWire to
cclude the distal vessel during balloon angioplasty and
tent deployment, followed by aspiration of atherosclerotic
ebris from the SVG using the Export aspiration catheter
Medtronic Inc.), before the occlusion balloon was deflated
nd antegrade flow was restored. Additional details of the
uardWire system and its use have been described previ-
usly (9).
ssessment of in-hospital outcomes and clinical follow-
p. Case report forms concerning baseline demographic
nd clinical data, procedural details, and clinical outcomes
uring the initial hospitalization and 30-day follow-up
eriod were completed by a research coordinator at each
ite, source-verified by independent data monitors, and
ubmitted to the data coordinating center. All end points
death, MI, repeat revascularization) were reviewed by an
Abbreviations and Acronyms
CK-MB creatinine kinase-MB
MI  myocardial infarction
PCI  percutaneous coronary intervention
SAFER  Saphenous Vein Graft Angioplasty Free of
Emboli Randomized trial
SVG  saphenous vein bypass graftndependent clinical events committee who were blinded to lreatment assignment. Myocardial infarction was defined as
levation of creatinine kinase-MB (CK-MB) 3 the
pper limit of normal at any time during the follow-up
eriod. Large MI was defined prospectively as any MI with
peak CKMB 5 the upper limit of normal or any
-wave MI. Hemorrhagic complications included the need
or vascular surgical repair, ultrasound-guided compression,
r bleeding requiring transfusion.
ummary of principal clinical outcomes. As reported
reviously, the primary end point of the SAFER trial was
he composite of death, MI, or repeat revascularization of
he target vessel at 30 days, which was reduced from 16.5%
n the control group to 9.6% in the GuardWire group (42%
elative risk reduction, p  0.004) (9). This difference was
riven primarily by a 42% reduction in the incidence of MI
ith the GuardWire (8.6% vs. 14.2%, p  0.008). There
ere also parallel trends toward reduced 30-day mortality
1.0% vs. 2.5%, p  0.11) and repeat bypass surgery (0.0%
s. 0.5%, p  0.24) with the GuardWire.
etermination of medical care costs. Medical care costs
or the initial hospitalization and for the 30-day follow-up
eriod were assessed using a combination of “bottom-up”
nd “top-down” methods as previously described (12).
ARDIAC CATHETERIZATION LABORATORY COSTS. De-
ailed resource utilization was recorded for each procedure,
nd the cost of each item was estimated based on the mean
ospital acquisition cost for the item in 2001. Costs of
dditional disposable equipment, overhead, and deprecia-
ion for the cardiac catheterization laboratory, and nonphy-
ician personnel were estimated on the basis of the average
ost per procedure at Beth Israel Deaconess Medical Center
n 2001 and adjusted for actual procedure duration. The cost
f each GuardWire device was set at $1,500 based on its
urrent sales price.
THER HOSPITAL COSTS. All other hospital costs were
etermined using “top-down” accounting methods based on
ach hospital’s annual Medicare cost report. Itemized bills
ere obtained for each patient’s initial hospitalization and
ny subsequent cardiovascular hospitalizations during the
ollow-up period. Hospital costs were determined by mul-
iplying itemized hospital charges by the cost-center specific
ost-to-charge ratio obtained from the hospital’s Medicare
ost report. Previous studies from our group and others have
hown this method to correlate well with data from detailed
ost accounting systems (13,14). All costs were converted to
001 dollars based on the medical care component of the
onsumer Price Index.
For those admissions with missing billing information
n  123, 14%), nonprocedural hospital costs were imputed
ased on a linear regression model developed using the
ospital admissions for which complete billing information
ere available (n  776). Independent variables for this
odel included age, length of stay, intensive care unitength of stay, bleeding complications, revascularization
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November 2, 2004:1801–8 Cost-Effectiveness of Distal Embolic Protectionrocedures, and diagnostic catheterization (model R2 
.75).
THER COSTS. Utilization of selected outpatient services
uring follow-up (physician office visits, emergency depart-
ent visits, echocardiograms, and stress tests) was estimated
y patient self-report, and costs for these services were
alculated based on 2001 Medicare reimbursement rates.
hysician’s fees for inpatient and outpatient services, major
ardiac procedures, and surgical procedures were based on
he 2001 Medicare fee schedule.
tatistical analysis. Discrete data are reported as frequen-
ies, while continuous data are reported as mean  SD.
ost data are reported as both mean and median values.
iscrete variables were compared by Fisher exact test.
ormally distributed continuous variables were compared
y Student t test. Cost and other nonnormally distributed
ata (length of stay, procedure duration) were compared by
he Wilcoxon rank-sum test. All statistical analyses and
ost-effectiveness analyses were performed according to the
ntention-to-treat principle.
ost-effectiveness analysis. Because use of the Guard-
ire was the more costly strategy, we performed a formal
ost-effectiveness analysis to compare the clinical benefits
ith the net cost of distal protection. Because empiric
utcomes data were only collected for the 30-day follow-up
eriod, we developed a probabilistic model to project long-
erm survival beyond the study observation period, contin-
ent on the observed 30-day outcomes. Details of the model
re described in the Appendix. The primary end point for
he cost-effectiveness analysis was the incremental cost per
ear of life gained for PCI using the GuardWire compared
ith conventional PCI. This cost-effectiveness ratio was
alculated by dividing the difference in mean 30-day med-
cal care costs for the two treatment groups by the difference
n life expectancy, derived from the long-term survival
odel. We used identical methods to estimate differences in
ost, life-expectancy, and incremental cost-effectiveness for
everal prespecified subgroups according to angiographic,
linical, and treatment-specific factors. Bias-corrected con-
dence intervals for the cost-effectiveness ratios were esti-
ated by the bootstrap method, using 1,000 resamplings of
he study population (15). Although future costs beyond the
0-day trial period were not included in our primary analysis
16,17), additional costs of $2,635 per year (18) were
onsidered in sensitivity analyses. In addition to these
ong-term analyses, we calculated a “within-trial” cost-
ffectiveness analysis in which the cost-effectiveness ratio
as expressed as cost per death or MI avoided (based on the
rimary study end points).
ESULTS
atient population. Baseline characteristics of the two
reatment groups were well-matched (Table 1). The mean
ge was 69  10 years. Approximately one-third of the
opulation had diabetes mellitus, and more than 90% had vultivessel coronary disease. The mean ejection fraction
as mildly reduced at 48  12%. The median graft age was
0 years, and 40% of lesions contained angiographically
vident thrombus.
rocedural resource utilization and cost. Table 2 sum-
arizes resource utilization and cost for the index revascu-
arization procedures. Mean procedure duration was in-
reased by 8 min for patients assigned to the GuardWire
ompared with the control group. Other than the Guard-
ire itself, there were no other differences in procedural
esource utilization between the two treatment groups
ncluding the numbers of balloon catheters, stents, and the
se of planned or bailout glycoprotein IIb/IIIa inhibitors.
nitial procedural costs were $1,600 per patient higher for
he GuardWire group compared with the control group
$6,326  $1,873 [median $6,012] vs. $4,779  $1,771
median $4,414], p  0.001)—driven primarily by the cost
f the GuardWire itself.
nitial hospital outcomes, resource utilization, and costs.
able 3 summarizes initial hospital outcomes for the two
reatment groups. Although there was no significant differ-
nce in in-hospital mortality between the GuardWire and
ontrol groups (0.7% vs. 1.0%, p  0.72), patients random-
zed to the GuardWire had a significantly lower incidence of
eriprocedural MI during the index hospitalization (8.4%
s. 13.9%, p  0.01). Although the relative risk reductions
ere similar for small and large MI (48% and 42%,
espectively), approximately two-thirds of the absolute risk
eduction for MI was due to prevention of large MI
CK-MB 5 upper limit of normal). In addition, the
uardWire strategy was associated with a modest reduction
n the incidence of bleeding complications compared with
onventional treatment (5.4% vs. 7.1%, p  0.38). These
ower rates of ischemic and hemorrhagic complications led
o a significant reduction in postprocedure length of stay for
he GuardWire group compared with the control group (2.7
able 1. Baseline Clinical and Angiographic Characteristics
GuardWire Group
(n  406)
Control Group
(n  395)
ge, yrs 68  10 69  9
ender, % male 82 84
iabetes mellitus, % 33 34
urrent smoker, % 10 11
rior myocardial infarction, % 61 64
umber of diseased vessels
1 6 5
2 20 16
3 74 79
jection fraction, % 48  12 47  12
ein graft age, yrs
(median [25th, 75th percentile])
10 (7, 13) 11 (7, 15)
ngiographic thrombus, % 38 40
IMI flow grade 3, % 14 12
esion length, mm 15.6  9.1 16.6  11.2
 NS for all between group comparisons.
TIMI  Thrombolysis In Myocardial Infarction.s. 3.0 days, p  0.003).
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Cost-Effectiveness of Distal Embolic Protection November 2, 2004:1801–8As a result, hospital room and ancillary costs were$900
er patient lower for the GuardWire group compared with
onventional treatment ($4,647 vs. $5,514, p  0.02).
here were no significant differences in either repeat pro-
edure costs or physician costs during the index hospital-
zation. When combined with the higher initial procedure
osts, the net effect of the GuardWire on hospital costs was
n increase of $600 per patient ($13,172  $5,665
median $11,639] vs. $12,590  $6,252 [median $10,770],
 0.001).
ollow-up resource utilization and costs. Between hos-
ital discharge and 30-day follow-up, there were trends
oward reduced rates of death (0.3% vs. 1.6%, p 0.06) and
onfatal MI (0.5% vs. 1.6%, p  0.17) in the GuardWire
Table 2. Procedural Resource Utilization and C
GuardWire
(n  4
Procedure duration, min 53
Contrast volume, ml 189
GuardWires 1.2
Balloon catheters 0.7
Stents 1.4
GP IIb/IIIa inhibitor used, % 60.0
Planned 57.1
Unplanned 2.9
Resource costs
Room/overhead $1,015  30
Supplies/drugs $995  65
Devices (including GuardWire) $4,209  1,4
Personnel* $107 35
Total procedural cost $6,326 1,8
*Excluding physician services. Values in parentheses are med
GP  glycoprotein.
Table 3. Initial Hospital Outcomes, Resource
GuardWire
(n  4
Death, % 0.7
Nonfatal MI, %
Any 8.4
Large MI (CK-MB 5) 5.2
Small MI (CK-MB 3 to 5) 3.2
Repeat revascularization, %
Any 1.2
PCI 1.2
CABG 0.0
Diagnostic catheterization, % 1.0
Hemorrhagic complication, % 5.4
Length of stay, days
Total 4.0  3.
ICU/CCU 0.8 2.
Postprocedure 2.7 2.
Medical costs
Initial procedure $6,326 1,87
Repeat procedures $66 557
Hospital room/ancillary $4,647 3,94
MD fees $2,133  $62
Total $13,172 5,16
Values in parentheses are medians.
CABG  coronary artery bypass surgery; CK-MB  creatin
percutaneous coronary intervention; MI  myocardial infarction.roup (Table 4). All deaths (both in-hospital and during
ollow-up) were adjudicated as cardiac by the clinical events
ommittee. When these results were combined with the
bserved in-hospital outcomes, use of the GuardWire was
ssociated with a 42% reduction in the 30-day risk of death
r any MI (95% confidence interval, 17% to 65%) and a 44%
eduction in the risk of death or large MI (95% confidence
nterval, 10% to 68%). There were no significant differences
n rates of rehospitalization or repeat revascularization
rocedures during follow-up, however. Follow-up medical
are costs for revascularization procedures, hospital services,
nd outpatient care were virtually identical for the two
reatment groups, and cumulative 30-day costs remained
625 per patient higher for the GuardWire group compared
up Control Group
(n  395) p Value
45  33 0.001
177  98 0.08
0.04  0.2 0.001
0.8  0.9 0.17
1.4  0.8 0.57
62.5 0.48
58.7 0.65
3.8 0.42
4) $947  295 ($866) 0.001
1) $977  642 ($796) 0.31
3,645) $2,756  1,299 ($2,050) 0.001
) $99 33 ($90) 0.001
,012) $4,779 1,771 ($4,414) 0.001
ation, and Cost
up Control Group
(n  395) p Value
1.0 0.72
13.9 0.01
8.9 0.05
5.1 0.21
1.3 1.00
0.8 0.73
0.5 0.24
1.3 0.75
7.1 0.38
4.4 3.2 (2) 0.07
0.9 2.2 (0) 0.79
3.0 2.4 (1) 0.003
,012) $4,779 1,771 ($4,414) 0.001
$51 500 ($0) 0.83
,403) $5,514 4,886 ($3,982) 0.02
883) $2,246 966 ($1,945) 0.11
1,639) $12,590 6,252 ($10,770) 0.001ost
Gro
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November 2, 2004:1801–8 Cost-Effectiveness of Distal Embolic Protectionith conventional therapy ($14,399  $6,731 [median
12,259] vs. $13,774  $7,016 [median $11,534], p 
.006).
ultivariable analysis. To define more precisely those
actors that contributed to the net cost of GuardWire
reatment, we used multivariable linear regression to deter-
ine the impact of specific clinical outcomes, complica-
ions, and other factors on initial hospital costs (Table 5).
he model identified both procedure-related complications
death, large MI, hemorrhagic complications) and the need
or unplanned bypass surgery as the principal determinants
f hospital cost with incremental costs ranging from $6,671
for each major vascular complication) to $46,426 (for
n-hospital CABG).
We then estimated the absolute cost savings associated
ith prevention of specific clinical events by multiplying the
ndependent cost of each event by the difference in event
requency between the GuardWire and conventional treat-
ent groups. Of the $965 per patient savings in nonproc-
dural costs observed with GuardWire therapy, $310 were
ttributable to the observed reduction in periprocedural MI,
113 were attributable to reduced bleeding complications,
nd $83 were attributable to reduced mortality. An addi-
ional $237 in cost savings were related to the observed
eduction in in-hospital bypass surgery with GuardWire
herapy. The remaining $222 in cost savings were not
able 4. Follow-up Events, Resource Utilization, and Cost
GuardWire
(n  4
vents between discharge and 30 days
Death, % 0.3
Myocardial infarction, % 0.5
Repeat hospitalization, % 13.5
CABG 0.0
PCI 2.7
Office visits 0.9  0.8
Hospital days 0.6  2.3
ollow-up costs $1,248 3,73
umulative events (study entry to 30 days)
Death, % 1.0
Death or large MI, % 6.2
Death or any MI, % 9.6
otal costs (study entry to 30 days) $14,399  6,73
alues in parentheses are medians.
CABG  coronary artery bypass surgery; MI  myocardial infarction; PCI  p
able 5. Multivariable Linear Regression Model of Initial Hospit
Factor Estimated Cost* 95% CI
n-hospital CABG $46,426 $35,871–$56,981
eath $27,686 $21,642–$33,730
arge MI (CK-MB 5) $8,370 $6,215–$10,526
emorrhagic complication $6,671 $4,410–$8,932
otal expected
otal observed
odel R2 0.38. *Estimated cost of each complication derived from regression mode
t the p  0.001 level.
CABG  coronary artery bypass surgery; CI  confidence interval; CK-MB  creatnixplained by differences in in-hospital events and may
eflect differences in the intensity of care or severity of
omplications between the two treatment groups.
ost-effectiveness. Based on the observed 30-day clinical
utcomes and costs, the within-trial cost-effectiveness ratio
or GuardWire-based PCI compared with standard PCI
as $9,342 per death or MI avoided. On the basis of these
esults and projections from our long-term survival model,
e estimated a mean life expectancy (undiscounted) of
1.38 years for the GuardWire group and 11.16 years for
he conventional therapy group—a difference of 0.22 years.
fter discounting at 3% per year, the life expectancy
ifference was reduced to 0.17 years (95% confidence
nterval, 0.04 to 0.29 years). Thus, the lifetime incremental
ost-effectiveness ratio for GuardWire-based PCI compared
ith standard PCI without embolic protection was $3,718
er year of life gained (95% confidence interval, $0 to
43,079). Bootstrap simulation demonstrated that the cost-
ffectiveness ratio for embolic protection remained
$40,000 per life-year gained in 97.3% of samples (Fig. 1).
These results were relatively stable over a broad range of
lternative assumptions regarding long-term outcomes. For
xample, if we assumed that even large nonfatal MIs had no
rognostic significance, the life expectancy gain fell to 0.142
ears with an incremental cost-effectiveness ratio of $4,401
er life-year gained. On the other hand, if we assumed that
up Control Group
(n  395) p Value
1.6 0.06
1.6 0.17
14.7 0.68
0.0 1.00
4.2 0.33
0.9  0.8 (2) 0.81
0.4  1.5 (0) 0.80
47) $1,227 3,455 ($147) 0.82
2.5 0.11
10.9 0.02
16.5 0.008
2,259) $13,774 7,016 ($11,534) 0.006
eous coronary intervention.
osts
Incidence in
Control Group
Incidence in
GuardWire Group
Net Savings Associated
With GuardWire
(% of Expected)
0.5% 0.0% $237 (31.8)
1.0% 0.7% $83 (11.1)
8.9% 5.2% $310 (41.7)
7.1% 5.4% $113 (15.2)
$743
$965
transformed dependent-variable (initial hospital costs). Each covariate was significantGro
06)
(2)
(0)
7 ($1
1 ($1al C
l of unne kinase-MB; MI  myocardial infarction.
t
e
t
I
r

s
l
$
o
3
e

a
f
S
l
T
3
a
0
d
a
c

e
s
s
a
l
D
A
f
t
t
n
p
p
r
c
o
f
c
G
o
l
o
b
s
T
p
i
r
r
u
a
c
s
p
m
l
(
m
c
F
e
t
R
t
g
F
m
t
t
a
o
i
(
A
0
1806 Cohen et al. JACC Vol. 44, No. 9, 2004
Cost-Effectiveness of Distal Embolic Protection November 2, 2004:1801–8he GuardWire had no effect on 30-day mortality, the life
xpectancy gain decreased to 0.029 years with an incremen-
al cost-effectiveness ratio of $21,551 per life-year gained.
nclusion of future costs increased the cost-effectiveness
atio to $8,697 per life-year gained, but it remained
$40,000 per life-year gained in 96.5% of bootstrapped
amples. Varying the discount rate from 0% to 10% had
ittle effect on the cost-effectiveness ratio (range $2,915 to
5,619 per life-year gained). Finally, varying the relative risk
f death or large MI in a deterministic model based on the
0-day SAFER results demonstrated that the cost-
ffectiveness ratio for embolic protection remained
$40,000 per life-year gained over a broad range of
ssumptions encompassing the full 95% confidence interval
or the treatment effect (Fig. 2).
ubgroup analyses. Stratified analyses according to se-
ected baseline patient characteristics are summarized in
able 6. There were no significant interactions between
0-day outcomes (death or large MI) or costs and treatment
ssignment for each of the prespecified subgroups (all p 
.05). While use of the GuardWire was economically
ominant for patients with definite angiographic thrombus
nd for patients with focal lesions (length 10 mm), the
ost-effectiveness ratio for embolic protection remained
$20,000 per year of life saved for each of the subgroups
xamined. Given the reduced sample sizes inherent in
ubgroup analyses, these cost-effectiveness ratios were less
table than the overall trial results. Nonetheless, the prob-
bility that the cost-effectiveness ratio was $50,000 per
ife-year gained was 70% for each of the subgroups tested.
ISCUSSION
lthough the safety and effectiveness of embolic protection
or patients undergoing SVG PCI have been established (9),
igure 1. Cumulative distribution plot of the incremental cost-
ffectiveness ratio for embolic protection compared with conventional
reatment based on the Saphenous Vein Graft Angioplasty Free of Emboli
andomized trial (SAFER) results. As indicated by the arrow, 97.3% of
he bootstrapped cost-effectiveness ratios were $40,000 per year of life
ained.he overall cost and cost-effectiveness of such adjunctive pherapy were previously unknown. In this prospective eco-
omic study, we found that use of the GuardWire embolic
rotection device increased initial PCI costs by$1,600 per
atient compared with standard of care. However, by
educing major ischemic complications (which were both
ommon and costly in this patient population), nearly 60%
f this initial cost difference was recouped over the 30-day
ollow-up period. As a result, overall 30-day medical care
osts were increased by $650 per patient with use of the
uardWire.
Whether this modest cost increase is warranted depends
n the extent to which embolic protection improves either
ong-term survival or quality of life compared with standard
f care. Given the relatively short time-frame encompassed
y the SAFER trial, we did not believe that there would be
ufficient time for quality-of-life differences to emerge.
hus, quality-of-life was not assessed for the trial partici-
ants. On the other hand, embolic protection reduced the
ncidence of 30-day death or MI by 42% (with consistent
elative reductions in both death and large MI). When these
esults were incorporated into a statistical survival model,
se of the GuardWire was projected to increase life expect-
ncy by an average of 0.22 years compared with standard
are, with a cost-effectiveness ratio of $3,700 per year of life
aved. Thus, the cost-effectiveness of embolic protection for
atients undergoing SVG PCI compares very favorably with
any accepted medical interventions including lipid-
owering therapy for secondary coronary prevention
$4,000 per year of life saved) (19), bypass surgery for left
ain disease ($10,000 per year of life saved) (20), and
hronic hemodialysis for end-stage renal disease ($50,000
igure 2. Impact of variations in the relative risk of death or large
yocardial infarction (MI) with the GuardWire versus conventional
reatment on the incremental cost-effectiveness ratio for embolic protec-
ion. Life expectancy projections for this sensitivity analysis were based on
Markov model of long-term survival contingent on 30-day rates of death
r large MI after saphenous vein bypass graft percutaneous coronary
ntervention (Appendix). The arrow indicates the 95% confidence interval
CI) for the relative risk of death or MI based on the Saphenous Vein Graft
ngioplasty Free of Emboli Randomized trial (SAFER) results (0.21 to
.92).er year of life saved) (21). The results of this study,
t
c
n
s
a
h
W
s
w
w
l
p
u
p
p
t
w
h
s
a
r
b
s
s
H
o
c
f
m
t
p
m
R
o
p
h
d
c
a
p
t
c
A
s
S
n
c
G
S
e
t
S
t
b
m
c
s
t
p
(
p
s
T
p
f
t
t
g
w
a
d
l
s
u
T
O
G
G
A
L
* ent of
ife-yea
1807JACC Vol. 44, No. 9, 2004 Cohen et al.
November 2, 2004:1801–8 Cost-Effectiveness of Distal Embolic Protectionherefore, suggest that distal embolic protection is highly
ost-effective for patients undergoing SVG PCI and should
ot be withheld from such patients on the basis of cost.
Although our cost-effectiveness analysis was based on
tatistical projections of long-term survival and life expect-
ncy, our model was based on several assumptions that may
ave biased our results to some extent against the Guard-
ire. First, although several observational studies have
uggested that even small periprocedural MIs are associated
ith a worse prognosis after PCI (especially among patients
ith severe underlying coronary artery disease and reduced
eft ventricular function) (22), we assumed that only larger
eriprocedural MIs (with CK-MB elevations 5 the
pper limit of normal) would adversely affect long-term
rognosis after PCI. Second, we assumed that the adverse
rognosis associated with periprocedural MI was limited to
he first year of follow-up, beyond which survival curves
ould remain parallel. To the extent that previous studies
ave generally demonstrated continued divergence of the
urvival curves beyond the first year of follow-up (23), this
ssumption of time-limited prognostic significance also
epresents a conservative assumption that would likely have
iased our study against the GuardWire. Finally, we as-
umed there would be no further differences in cost (among
urviving patients) beyond those seen in the first 30 days.
owever, it is likely that patients with large MIs at the time
f PCI would have experienced higher long-term follow-up
osts than patients without procedural complications (e.g.,
or the management of congestive heart failure or arrhyth-
ias). Considering the conservative nature of these assump-
ions, it is likely that the cost-effectiveness of embolic
rotection for patients undergoing SVG PCI may be even
ore favorable than we have estimated.
ole of risk-stratification. With any costly new technol-
gy, there is a natural tendency for clinicians as well as
olicymakers to target the initial use of these therapies to
igher risk populations. The value of this approach clearly
able 6. Subgroup Analyses of Efficacy, Cost, and Cost-Effective
Subgroup
Relative Risk of Death
or Large MI (95% CI)*
30-Day
verall 0.54 (0.32, 0.90) $625
P IIb/IIIa inhibitor
Not planned 0.38 (0.15, 0.96) $970
Planned 0.64 (0.34, 1.19) $446
raft age
8 yrs 0.61 (0.21, 1.75) $1,208
8 yrs 0.51 (0.28, 0.93) $312
ngiographic thrombus
Absent 0.57 (0.27, 1.21) $1,305
Present 0.47 (0.23, 0.99) $659
esion length
10 mm 0.47 (0.08, 2.63) $443
10–20 mm 0.54 (0.24, 1.20) $619
20 mm 0.57 (0.26, 1.23) $1,272
Relative risk or cost difference between GuardWire group and control group; †Perc
C/E  cost-effectiveness; CI  confidence interval; GP  glycoprotein; LY  lepends on one’s ability to predict reliably the occurrence of pomplications as well as on the balance of costs and risks
ssociated with the new technology. In the case of embolic
rotection for SVG PCI, our analysis suggests that efforts to
arget therapy are unlikely to substantially improve the
ost-effectiveness of this technology at the present time.
lthough one can certainly identify higher and lower risk
ubgroups within the population of patients undergoing
VG intervention, even the lower-risk populations have a
ontrivial probability of major complications and a signifi-
ant reduction in those complications by use of the
uardWire. As a result, subgroup analyses within the
AFER population demonstrated uniformly favorable cost-
ffectiveness ratios (although with greater variability due to
he reduced sample size).
tudy limitations. This study has several important limi-
ations. The primary limitation is the lack of empiric data
eyond the 30-day trial period, thus necessitating extensive
odeling of long-term survival to develop a meaningful
ost-effectiveness analysis. Nonetheless, use of relatively
hort-term outcomes is common in cardiovascular clinical
rials, and many previous cost-effectiveness studies have
erformed similar extrapolations based on six-month
17,24) or even in-hospital (25,26) data. Moreover, as noted
reviously, whenever possible we made conservative as-
umptions so as to bias our analysis against the GuardWire.
hus, it is likely that the cost-effectiveness of embolic
rotection for patients undergoing SVG PCI is even more
avorable than we have estimated. Like many device trials,
he SAFER trial was conducted at selected sites; whether
he clinical and economic outcomes we observed can be
eneralized to all PCI programs is unknown. Finally, as
ith any clinical trial, the results of this cost-effectiveness
nalysis apply only to the study population—patients un-
ergoing SVG intervention—and should not be extrapo-
ated to other populations at high risk of distal embolization
uch as thrombotic native coronary lesions or patients
ndergoing primary PCI for acute MI or to other embolic
t Difference
CI)*
C/E Ratio
($/LY Gained)
Percent of C/E ratios
<$50,000 per LY gained†
8, $1,578) $3,718 97.8
6, $2,256) $6,480 91.6
8, $1,771) $4,474 93.4
8, $2,815) $18,356 71.9
0, $1,503) $2,045 98.5
, $2,496) $15,321 83.3
276, $959) Dominant 99.4
323, $1,435) Dominant 91.1
5, $2,084) $5,604 93.3
6, $3,070) $7,445 88.4
cost-effectiveness ratios $50,000 per year of life gained by bootstrap analysis.
r; MI  myocardial infarction.ness
Cos
(95%
($32
($31
($87
($39
($88
($114
($2,
($2,
($84
($52rotection devices.
C
d
s
m
3
n
t
f
r
i
s
W
s
s
d
t
c
R
C
3
d
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
A
F
1808 Cohen et al. JACC Vol. 44, No. 9, 2004
Cost-Effectiveness of Distal Embolic Protection November 2, 2004:1801–8onclusions. Based on the results of the SAFER trial,
istal protection using the GuardWire balloon occlusion
ystem significantly improves the safety of SVG PCI while
odestly increasing initial hospital costs and aggregate
0-day costs compared with standard care. Formal eco-
omic analysis demonstrates that the cost-effectiveness of
he GuardWire in patients undergoing SVG PCI is highly
avorable compared with accepted medical interventions and
emains reasonable over a wide range of alternative model-
ng assumptions and patient subgroups. These findings
uggest that, for patients undergoing SVG PCI, the Guard-
ire embolic protection system is an attractive use of scarce
ocietal resources. Further studies are needed to demon-
trate the cost-effectiveness of alternative embolic protection
evices for SVG PCI, and to extend the results of this study
o other PCI populations at high risk of embolic
omplications.
eprint requests and correspondence: Dr. David J. Cohen,
ardiovascular Division, Beth Israel Deaconess Medical Center,
30 Brookline Avenue, Boston, Massachusetts 02215. E-mail:
cohen@caregroup.harvard.edu.
EFERENCES
1. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme
elevation following successful saphenous vein graft intervention is
associated with late mortality. Circulation 1999;100:2400–5.
2. de Feyter PJ, Serruys P, van den Brand M, et al. Percutaneous
transluminal angioplasty of a totally occluded venous bypass graft: a
challenge that should be resisted. Am J Cardiol 1989;64:88–90.
3. Weintraub WS, Jones EL, Morris DC, et al. Outcome of reoperative
coronary bypass surgery versus coronary angioplasty after previous
bypass surgery. Circulation 1997;95:868–77.
4. Holmes DR, Topol EJ, Califf RM, et al. A multicenter, randomized
trial of coronary angioplasty versus directional atherectomy for
patients with saphenous vein bypass graft lesions. Circulation
1995;91:1966 –74.
5. Dooris M, Hoffmann M, Glazier S, et al. Comparative results of
transluminal extraction coronary atherectomy in saphenous vein graft
lesions with and without thrombus. J Am Coll Cardiol 1995;25:
1700–5.
6. Kuntz RE, Baim DS, Cohen DJ, et al. A randomized prospective
multicenter trial comparing vacuum thrombectomy to intracoronary
urokinase for coronary and vein graft thrombus: results of the Vein
Graft Angiojet study (VeGAS 2). Am J Cardiol 2002;89:326–30.
7. Savage MP, Douglas JS, Fischman DL, et al. Stent placement
compared with balloon angioplasty for obstructed coronary bypass
grafts. N Engl J Med 1997;337:740–7.
8. Roffi M, Mukherjee D, Chew DP, et al.Lack of benefit from
intravenous platelet glycoprotein IIb/IIIa receptor inhibition as ad-
junctive treatment for percutaneous interventions of aortocoronary
bypass grafts: a pooled analysis of five randomized clinical trials.
Circulation 2002;106:3063–7. J9. Baim DS, Wahr D, George B, et al. Randomized trial of a distal
embolic protection device during percutaneous intervention of saphe-
nous vein aorto-coronary bypass grafts. Circulation 2002;105:1285–
90.
0. Cohen DJ, Ramee S, Baim DS, et al. Economic assessment of
rheolytic thrombectomy vs. intracoronary urokinase for treatment of
extensive intracoronary thrombus: results from a randomized clinical
trial. Am Heart J 2001;142:648–56.
1. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term
“cost effective” in medicine. N Engl J Med 1986;314:253–6.
2. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one-year
economic outcomes after coronary stenting or balloon angioplasty:
results from a randomized clinical trial. Circulation 1995;92:2480–7.
3. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: how
good a basis for estimating hospital costs. Inquiry 1995;32:476–81.
4. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic
approaches for the economic evaluation of new technologies alongside
multicenter clinical trials. Am Heart J 2003;145:452–8.
5. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York,
NY: Chapman & Hall, 1993.
6. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of
thrombolytic therapy with tissue plasminogen activator as compared
with streptokinase for acute myocardial infarction. N Engl J Med
1995;332:1418–24.
7. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness
of an early invasive vs. conservative strategy for the treatment of unstable
angina and non–ST-segment elevation myocardial infarction.
JAMA 2002;288:1851–8.
8. Reynolds MR, Neil N, Ho KKL, et al. Clinical and economic
outcomes of multivessel coronary stenting compared with bypass
surgery: a single-center U.S. experience. Am Heart J 2003:145:334–
42.
9. Johannesson M, Jonsson B, Kjekshus J, et al.Cost effectiveness of
simvastatin treatment to lower cholesterol levels in patients with
coronary heart disease. N Engl J Med 1997;336:332–6.
0. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery
bypass surgery. Circulation 1982;66:III56–66.
1. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health
economic evaluations: the special case of end-stage renal disease
treatment. Med Decis Making 2002;22:417–30.
2. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after
revascularization procedures. J Am Coll Cardiol 1998;31:241–51.
3. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG.
Significance of mild transient release of creatine kinase-MB frac-
tion after percutaneous coronary interventions. Circulation 1996;
94:528 –36.
4. Mark D, Harrington R, Lincoff A, et al. Cost-effectiveness of platelet
glycoprotein IIb/IIIa inhibition with eptifibatide in patients with
non–ST-elevation acute coronary syndromes. Circulation 1999;101:
366–71.
5. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost-
effectiveness of thrombolytic therapy with streptokinase in elderly
patients with suspsected acute myocardial infarction. N Engl J Med
1992;327:7–13.
6. Weintraub WS, Thompson TD, Culler S, et al. Targeting patients
undergoing angioplasty for thrombus inhibition: a cost-effectiveness
and decision support model. Circulation 2000;102:392–8.
PPENDIX
or the Appendix, please see the November 2, 2004, issue of
ACC at www.onlinejacc.org.
